{"organizations": [], "uuid": "4fcaf62d9957e193fd000f7b08dd9921d6da9cd5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.reuters.com", "main_image": "https://s3.reutersmedia.net/resources/r/?m=02&d=20180212&t=2&i=1230628455&w=1200&r=LYNXMPEE1B0LP", "site_section": "http://feeds.reuters.com/reuters/UKHealthNews", "section_title": "Reuters: Health News", "url": "https://uk.reuters.com/article/uk-norway-biogen/norway-to-buy-biogens-spinraza-medicine-broadcaster-nrk-idUKKBN1FW0U1", "country": "US", "domain_rank": 408, "title": "Norway to buy Biogen's Spinraza medicine: broadcaster NRK", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-12T12:07:00.000+02:00", "replies_count": 0, "uuid": "4fcaf62d9957e193fd000f7b08dd9921d6da9cd5"}, "author": "", "url": "https://uk.reuters.com/article/uk-norway-biogen/norway-to-buy-biogens-spinraza-medicine-broadcaster-nrk-idUKKBN1FW0U1", "ord_in_thread": 0, "title": "Norway to buy Biogen's Spinraza medicine: broadcaster NRK", "locations": [], "entities": {"persons": [{"name": "terje solsvik", "sentiment": "none"}, {"name": "gwladys fouche", "sentiment": "none"}], "locations": [{"name": "norway", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "nrk", "sentiment": "negative"}, {"name": "biogen", "sentiment": "negative"}, {"name": "min read  oslo", "sentiment": "none"}, {"name": "nrk reuters staff", "sentiment": "none"}, {"name": "biogen inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 12, 2018 / 10:08 AM / Updated 10 hours ago Norway to buy Biogen's Spinraza medicine - broadcaster NRK Reuters Staff 1 Min Read \nOSLO (Reuters) - Norwegian authorities will buy the rare-disease treatment Spinraza for patients from U.S. drugmaker Biogen Inc( BIIB.O ) at a cost of 7 million Norwegian crowns (635,883.95 pounds) per year per patient, public broadcaster NRK reported on Monday. \nSpinraza treats the rare, often fatal disease spinal muscular atrophy (SMA). Norwegian authorities will cover the costs for minors only. Reporting by Gwladys Fouche, editing by Terje Solsvik", "external_links": [], "published": "2018-02-12T12:07:00.000+02:00", "crawled": "2018-02-12T12:29:32.065+02:00", "highlightTitle": ""}